Acumen Pharmaceuticals expects topline results from its sabirnetug Phase 2 study in late 2026 and is targeting a mid-2027 IND filing for an EBD candidate. The company says successful Phase 2 results could support faster sabirnetug development with a partner while advancing the next-generation program.

Key Highlights

  • Acumen Pharmaceuticals held its Investor Day on September 16, with a live webcast and presentation.
  • Acumen Pharmaceuticals expects topline results from the sabirnetug Phase 2 study in late 2026.
  • Acumen Pharmaceuticals says successful Phase 2 results could support expedited sabirnetug development with a partner.

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) expects topline results from its Phase 2 sabirnetug study in late 2026. The company is also targeting a mid-2027 investigational new drug filing for a candidate using Enhanced Brain Delivery technology.

Investor Day Details and Pipeline Timetable

The agenda covered AβO-directed therapies, sabirnetug’s mechanism of action, the ALTITUDE-AD Phase 2 study and the EBD program, followed by questions and answers.

Alzheimer’s Market and Development Context

It also identified about 5 million people with early Alzheimer’s disease in the United States and about 2 million with mild cognitive impairment. The presentation listed annualized run rates of approximately $0.7B and $0.5B for the approved products shown.